Introduction
Pantothenate Kinase-Associated Neurodegeneration (PKAN), formerly known as Hallervorden-Spatz syndrome, represents the most common form of neurodegeneration with brain iron accumulation (NBIA), accounting for approximately 50-70% of all NBIA cases. PKAN is an autosomal recessive disorder caused by mutations in the PANK2 gene, which encodes pantothenate kinase 2, a mitochondrial enzyme essential for the first and rate-limiting step in coenzyme A (CoA) biosynthesis. [@zhou2011]
The disease is characterized by progressive neurodegeneration with prominent iron deposition in the globus pallidus and substantia nigra pars reticulata (SNr), leading to a constellation of movement disorders including dystonia, dysarthria, rigidity, and Parkinsonism. The hallmark radiological finding is the "eye-of-the-tiger" sign on brain MRI, reflecting the unique pattern of iron deposition with central hyperintensity surrounded by hypointensity in the globus pallidus.
Globus pallidus neurons are particularly vulnerable in PKAN due to their high metabolic demands, unique iron-handling properties, and the critical role of CoA in their normal function. Understanding the molecular mechanisms underlying PKAN pathogenesis provides insights not only into this rare disorder but also into broader questions of iron metabolism, mitochondrial function, and neurodegeneration relevant to more common conditions like Parkinson's disease and Huntington's disease.
Overview
...Introduction
Pantothenate Kinase-Associated Neurodegeneration (PKAN), formerly known as Hallervorden-Spatz syndrome, represents the most common form of neurodegeneration with brain iron accumulation (NBIA), accounting for approximately 50-70% of all NBIA cases. PKAN is an autosomal recessive disorder caused by mutations in the PANK2 gene, which encodes pantothenate kinase 2, a mitochondrial enzyme essential for the first and rate-limiting step in coenzyme A (CoA) biosynthesis. [@zhou2011]
The disease is characterized by progressive neurodegeneration with prominent iron deposition in the globus pallidus and substantia nigra pars reticulata (SNr), leading to a constellation of movement disorders including dystonia, dysarthria, rigidity, and Parkinsonism. The hallmark radiological finding is the "eye-of-the-tiger" sign on brain MRI, reflecting the unique pattern of iron deposition with central hyperintensity surrounded by hypointensity in the globus pallidus.
Globus pallidus neurons are particularly vulnerable in PKAN due to their high metabolic demands, unique iron-handling properties, and the critical role of CoA in their normal function. Understanding the molecular mechanisms underlying PKAN pathogenesis provides insights not only into this rare disorder but also into broader questions of iron metabolism, mitochondrial function, and neurodegeneration relevant to more common conditions like Parkinson's disease and Huntington's disease.
Overview
| Property | Value |
|----------|-------|
| Category | Neurodegeneration with Brain Iron Accumulation (NBIA) |
| Inheritance | Autosomal recessive |
| Gene | PANK2 (Pantothenate Kinase 2) |
| Chromosome | 20p12.3 |
| Protein | Mitochondrial pantothenate kinase |
| Enzyme Function | First step in CoA biosynthesis |
| Prevalence | 1-2 per million; ~50% of NBIA cases |
| Age of Onset | Childhood (typical), adulthood (atypical) |
| Primary Brain Regions | Globus pallidus (GPi/GPe), substantia nigra |
PANK2 Gene and Protein
Gene Structure
The PANK2 gene spans approximately 21 kb on chromosome 20p12.3 and contains 10 exons encoding a 512-amino acid protein. The protein localizes to the mitochondrial matrix, where it functions as a homodimer.
Enzyme Function
Pantothenate kinase (PanK) catalyzes the phosphorylation of vitamin B5 (pantothenate) to produce 4'-phosphopantothenate, the first and rate-limiting step in CoA biosynthesis:
Pantothenate + ATP → 4'-Phosphopantothenate + ADP
Four human pantothenate kinase isoforms exist (PANK1-4), with PANK2 being the mitochondrial isoform essential for CoA synthesis in tissues with high energy demands, including the brain.
Mutations
Over 150 pathogenic PANK2 mutations have been identified, including:
- Missense mutations: Most common; often affect enzyme stability or activity
- Nonsense mutations: Associated with severe phenotype
- Splice site mutations: Often lead to truncated proteins
- Frameshift mutations: Generally cause null alleles
Genotype-phenotype correlations exist, with some mutations associated with classical (early-onset) vs. atypical (late-onset) presentations. [@kristiansen2017]
Central Role of CoA
Coenzyme A is a universal cofactor essential for:
- Energy metabolism: CoA is required for the tricarboxylic acid (TCA) cycle, fatty acid oxidation, and ATP production
- Biosynthetic pathways: Cholesterol, steroid hormones, and neurotransmitter synthesis
- Protein modification: Post-translational acylation of proteins
- Cellular signaling: Acyl-CoA species serve as signaling molecules
The brain has particularly high CoA requirements due to its high metabolic rate and complex lipid composition (CoA is essential for myelin formation).
CoA Homeostasis in Neurons
Neurons maintain CoA levels through:
De novo synthesis: PANK2-dependent pathway
Recycling: CoA is recycled from acyl-carnitine and pantetheine
Import: Limited pantothenate uptake across the blood-brain barrierIn PKAN, impaired PANK2 function leads to:
- Decreased CoA synthesis
- Accumulation of pantothenate
- Secondary effects on mitochondrial function
- Disruption of lipid metabolism
Pathogenic Mechanisms of CoA Deficiency
Multiple mechanisms link CoA deficiency to neurodegeneration: [@arber2020]
Mitochondrial dysfunction: Reduced CoA impairs TCA cycle function, reducing ATP production
Oxidative stress: Impaired mitochondrial function increases ROS production
Lipid dysregulation: Defects in myelin formation and neuronal membrane maintenance
Neurotransmitter synthesis: Acetyl-CoA is required for acetylcholine synthesisIron Homeostasis
The brain requires precise iron regulation:
- Iron entry: Transferrin-bound iron enters via the blood-brain barrier
- Cellular uptake: DMT1 (divalent metal transporter 1) and transferrin receptors
- Storage: Ferritin in neurons and glia
- Utilization: For mitochondrial function, neurotransmitter synthesis
Iron and Neurodegeneration
Excess iron is toxic through the Fenton reaction:
Fe²⁺ + H₂O₂ → Fe³⁺ + •OH + OH⁻
The hydroxyl radical (•OH) is highly reactive and damages proteins, lipids, and DNA.
Iron accumulation is observed in multiple neurodegenerative conditions: [@youdim2000]
- Parkinson's disease: Substantia nigra
- Huntington's disease: Striatum and cortex [@post1998]
- Alzheimer's disease: Hippocampus and cortex
- PKAN: Globus pallidus and substantia nigra
Why the Globus Pallidus?
The globus pallidus is particularly susceptible to iron accumulation due to:
- High metabolic rate and mitochondrial density
- Rich iron supply from the striatum
- Lower ferritin expression than other brain regions
- Unique iron-handling properties
Pathogenesis of PKAN
Primary Molecular Events
PANK2 mutation → Loss of pantothenate kinase activity
Reduced CoA synthesis → Cellular CoA deficiency
Mitochondrial dysfunction → Reduced ATP, increased ROS
Iron dysregulation → Enhanced iron uptake/retention
Neurodegeneration → Cell death in GP and SNrSecondary Pathogenic Mechanisms
Oxidative Stress: CoA deficiency impairs mitochondrial respiration, increasing ROS production. Iron accumulation exacerbates oxidative stress through Fenton chemistry.
Lipid Dysregulation: CoA is essential for fatty acid metabolism and myelin synthesis. Disruption leads to membrane abnormalities and white matter changes.
Energy Failure: Reduced mitochondrial ATP production leads to neuronal dysfunction and death.
Excitotoxicity: Altered energy metabolism may impair glutamate transport, leading to excitotoxic damage.
Neuroinflammation: Reactive gliosis is observed in PKAN brains, potentially contributing to disease progression.
Role of Iron Accumulation
The relationship between CoA deficiency and iron accumulation remains an active area of investigation. Proposed mechanisms include: [@zhang2015]
Altered iron storage: CoA deficiency may affect ferritin function
Increased iron uptake: Upregulation of DMT1 and transferrin receptors
Impaired iron export: Reduced ferroportin function
Mitochondrial iron loading: Iron trapped in mitochondria due to impaired utilizationClinical Features
Classical (Early-Onset) PKAN
- Onset: Typically before age 6 years
- Initial symptoms: Gait difficulty, dystonia (often focal)
- Progression: Rapid, leading to wheelchair dependence within 10-15 years
- Core features:
- Progressive dystonia (generalized, axial > limb)
- Dysarthria (spastic or hypokinetic)
- Rigidity
- Parkinsonism (bradykinesia, tremor)
- Cognitive decline (variable)
- Ocular abnormalities (retinitis pigmentosa, optic atrophy)
Atypical (Late-Onset) PKAN
- Onset: Adolescence or adulthood (typically 10-30 years)
- Initial symptoms: Speech difficulty, psychiatric features
- Progression: Slower than classical form
- Core features:
- Dystonia (often focal,cranial)
- Dysarthria (prominent)
- Parkinsonism (prominent)
- Less severe cognitive impairment
Natural History
The natural history of PKAN has been characterized through natural history studies: [@hogarth2013]
- Early stage: Focal dystonia, mild gait disturbance
- Middle stage: Generalized dystonia, speech involvement, cognitive changes
- Late stage: Wheelchair dependence, severe motor impairment, complete dependency
- Complications: Respiratory failure, infections, contractures
Rating Scales
The PKAN Rating Scale (PKAN-RS) has been developed to assess: [@hogarth2013]
- Disability (ambulation, communication, swallowing)
- Motor symptoms (dystonia, parkinsonism)
- Non-motor symptoms (cognitive, behavioral)
Neuroimaging
MRI Findings
T2-weighted imaging:
- Eye-of-the-tiger sign: Central hyperintensity surrounded by hypointensity in the globus pallidus (pathognomonic)
- Hypointensity: Due to iron deposition in GPi and SNr
- Hyperintensity: Central area of gliosis and cavitation
Other sequences:
- T1: May show reduced signal in iron-affected regions
- SWI/GRE: Sensitive to iron deposition
- Diffusion: May show restricted diffusion in acute lesions
Imaging Evolution
Imaging changes typically precede clinical symptoms and progress over time:
- Early: Subtle hypointensity in GP
- Established: Eye-of-the-tiger sign
- Advanced: Atrophy of GP and SN, involvement of other regions
Advanced Imaging
- DTI: Shows decreased FA in affected regions
- MRS: May show elevated lactate (mitochondrial dysfunction)
- PET: Altered glucose metabolism in basal ganglia
Diagnosis
Diagnostic Criteria
Clinical diagnosis relies on:
Core features: Progressive movement disorder with iron accumulation on MRI
MRI findings: Eye-of-the-tiger sign
Genetic confirmation: Biallelic PANK2 mutationsDifferential Diagnosis
Other NBIA subtypes must be considered:
- PLAN (phospholipase A2, group VI): PLA2G6 mutations
- FA2H: FA2H mutations
- WDR45: WDR45 mutations (BPAN)
- COASY: COASY mutations (CoA biosynthesis)
- FHL1: FHL1 mutations
- PKAN-like (PKANL): PANK2 mutations without typical MRI
Genetic Testing
- Sequencing: PANK2 gene sequencing (full gene analysis)
- Deletions/duplications: MLPA or similar methods
- Carrier testing: For family members
- Prenatal testing: Possible for at-risk pregnancies
Management
Current Therapeutic Approaches
Symptomatic Management:
Dystonia treatment:
- Oral medications: Baclofen, benzodiazepines, anticholinergics (trihexyphenidyl)
- Botulinum toxin injections for focal dystonia
- Deep brain stimulation (DBS) of GPi
Parkinsonism treatment:
- Dopaminergic agents (levodopa, dopamine agonists)
- Variable response; often incomplete
Supportive care:
- Physical therapy
- Occupational therapy
- Speech therapy
- Nutritional support
- Respiratory care
Disease-Modifying Therapies
CoA Antagonist Therapy (CoA-AS): [@klopstock2019]
The CoA-antagonist pantethine has been tested to reduce CoA synthesis (creating a "functional rescue" by reducing toxic intermediates):
- Phase 2 trial showed some benefit in PKAN-RS scores
- Currently under investigation in larger trials
Coenzyme A Supplementation:
- Direct CoA administration is limited by blood-brain barrier penetration
- Phosphopantethine (a CoA precursor) has been explored
- Results have been mixed
Iron Chelation:
- Deferoxamine has been tried with limited success
- May slow iron accumulation but not reverse existing damage
Gene Therapy:
- AAV-PANK2 delivery under investigation
- Early-stage clinical trials planned
Deep Brain Stimulation
DBS of the internal segment of the globus pallidus (GPi-DBS) is an established treatment for severe dystonia in PKAN: [@bose2011]
- Target: GPi (internal segment)
- Outcomes: Significant reduction in dystonia scores
- Benefits: Particularly effective for generalized dystonia
- Limitations: Does not address underlying disease progression
Multi-Taxonomy Classification
Taxonomy Database Cross-References
| Taxonomy | ID | Name / Label |
|----------|-----|---------------|
| Cell Ontology (CL) | [CL:0000225](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000225) | globus pallidus neuron |
| Cell Ontology (CL) | [CL:0000540](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000540) | neuron |
| Cell Ontology (CL) | [CL:0000576](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000576) | GABAergic neuron |
| Uberon (UBERON) | [UBERON:0001906](https://www.ebi.ac.uk/ols4/ontologies/uberon/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FUBERON_0001906) | globus pallidus |
External Database Links
- [Cell Ontology (CL:0000225)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000225)
- [OBO Foundry (CL:0000225)](http://purl.obolibrary.org/obo/CL_0000225)
- [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
- [CellxGene Census](https://cellxgene.cziscience.com/)
- [Human Cell Atlas](https://www.humancellatlas.org/)
Animal Models
Available Models
- Pank2 knockout mice: Show some metabolic abnormalities but limited neurodegeneration
- Pank2 knockdown zebrafish: Model shows iron accumulation
- Cell models: Patient-derived neurons and iPSC models
Research Applications
- Understanding CoA metabolism in neurons
- Testing therapeutic compounds
- Gene therapy approaches
Future Directions
Gene therapy: AAV-mediated PANK2 delivery
CoA pathway modulators: Optimizing CoA-AS and CoA precursor approaches
Iron metabolism: Understanding iron accumulation and testing chelation
Biomarkers: Developing biomarkers for disease progression
Clinical trials: New therapeutic agents in clinical developmentSee Also
- [Neurodegeneration with Brain Iron Accumulation (NBIA) Overview](/diseases/nbia-overview)
- [PANK2 Gene](/genes/pank2)
- [Coenzyme A Biosynthesis Pathway](/mechanisms/coa-biosynthesis)
- [Iron Metabolism in Neurodegeneration](/mechanisms/iron-metabolism-neurodegeneration)
- [Globus Pallidus Function](/cell-types/globus-pallidus-neurons)
- [Deep Brain Stimulation for Movement Disorders](/therapeutics/deep-brain-stimulation)
- [Basal Ganglia Circuits](/mechanisms/basal-ganglia-circuits)
References
[Hayflick et al., PANK2 mutations in PKAN (2003)](https://doi.org/10.1212/01.WNL.0000059531.17754.7B)
[Gregory et al., Clinical features of NBIA (2009)](https://doi.org/10.1097/WCO.0b013e328328f0c8)
[Zhou et al., PANK2 mutations in Hallervorden-Spatz syndrome (2001)](https://doi.org/10.1038/ng718)
[Kell et al., Central role of CoA in human metabolism (2006)](https://doi.org/10.1016/j.mehy.2005.11.041)
[Leone et al., PKAN clinical management guidelines (2019)](https://doi.org/10.1016/j.ymgme.2019.02.009)
[Spiegel et al., Non-classical PKAN phenotypes (2006)](https://doi.org/10.1002/mds.21039)
[Arber et al., PANK2 and CoA metabolism (2020)](https://doi.org/10.1007/s12031-020-01552-5)
[Klopstock et al., CoA-antagonist therapy for PKAN (2019)](https://doi.org/10.1038/s41591-019-0358-8)
[Svetel et al., Dystonia in PKAN (2001)](https://doi.org/10.1002/mds.1173)
[Hogarth et al., PKAN rating scale (2013)](https://doi.org/10.1212/WNL.0b013e3182a8415a)
[Kristiansen et al., Genotype-phenotype in PKAN (2017)](https://doi.org/10.1093/brain/awx094)
[Zhang et al., Iron metabolism in PKAN (2015)](https://doi.org/10.1007/s12035-015-9301-0)
[Campolongo et al., CoA metabolism in PKAN (2012)](https://doi.org/10.1007/s10545-011-9407-4)
[Schneider et al., Natural history of PKAN (2016)](https://doi.org/10.1038/nrneurol.2015.225)
[Curtis et al., Ferritin mutations in NBIA (2002)](https://doi.org/10.1038/ng1049)
[Youdim & Riederer, Iron in brain and neurodegeneration (2000)](https://doi.org/10.1016/S0969-9961(00)00014-9)
[Post et al., Iron in Huntington's disease (1998)](https://doi.org/10.1097/00005072-199802000-00006)
[De \& Hayflick, Molecular basis of Hallervorden-Spatz (2002)](https://doi.org/10.1097/00008480-200212000-00005)